Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ: AXSM )

82.57 -1.21 (-1.44%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 655,015
Open 83.44
Bid (Size) 81.75 (1)
Ask (Size) 84.00 (1)
Prev. Close 83.78
Today's Range 82.31 - 85.14
52wk Range 64.11 - 105.00
Shares Outstanding 47,190,970
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
Axsome's AXS-05 met endpoints in Alzheimer's agitation studies, showing long-term safety and tolerability. FDA filing planned for late 2025. 
Via Benzinga
Exposures Product Safety
Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation
Shares of dropped Monday on mixed test results for its Alzheimer's disease agitation treatment. 
Via Investor's Business Daily

Performance

YTD
-5.44%
-5.44%
1 Month
-17.23%
-17.23%
3 Month
-1.16%
-1.16%
6 Month
+0.08%
+0.08%
1 Year
-8.69%
-8.69%

More News

Read More
Expert Outlook: Axsome Therapeutics Through The Eyes Of 8 Analysts
Via Benzinga
Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation
From Axsome Therapeutics, Inc.
Via GlobeNewswire
A Closer Look at 10 Analyst Recommendations For Axsome Therapeutics
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Breaking Down Axsome Therapeutics: 19 Analysts Share Their Views
Via Benzinga
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says
Via Benzinga
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
What Analysts Are Saying About Axsome Therapeutics Stock
Via Benzinga
Unveiling 14 Analyst Insights On Axsome Therapeutics
Via Benzinga
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
From Axsome Therapeutics, Inc.
Via GlobeNewswire
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Via The Motley Fool
Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12
From Axsome Therapeutics, Inc.
Via GlobeNewswire
1 Under-the-Radar Biotech Stock to Buy and Hold
Via The Motley Fool
Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Participate in Investor Conferences in September
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
From Axsome Therapeutics, Inc.
Via GlobeNewswire
New Study Reveals How Classical Music Could Revolutionize Depression Care
Via PressReach
Exposures Product Safety
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.